(Q38040419)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Luca Castagna

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Paolo Pedrazzoli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Alberto Bottini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Giovanni Rosti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Daniele Generali

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Simona Secondino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sandro Barni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Roberto Maisano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Francesco Lanza

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

4 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1505-1515

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22946512%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and onl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

The EBMT activity survey 2009: trends over the past 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Approach to the treatment of multiple myeloma: a clash of philosophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Rapid Delivery of Multiple High-Dose Chemotherapy Courses With Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.721767